A 24-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Add-On Compared to Uptitration of Metformin in Patients with Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Sub-Maximal Doses of Metformin. - PROMPT

ASTRAZENECA0 个研究点目标入组 454 人开始时间: 2009年7月20日最近更新: 2012年6月26日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: ASTRAZENECA
入组人数: 454

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Provision of informed consent prior to any study specific procedures. 2.Men or women who are ≥18 years of age at time of consenting upon Visit 1. 3.Clinical diagnosis of type 2 diabetes. 4.Treatment with metformin alone (any formulation) on stable doses of 1500 to 1700 mg per day for at least 8 weeks prior to Visit 1. 5.Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized. -WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea ≥12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level >35 mIU/mL). -Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (eg, vasectomy), should be considered to be of childbearing potential. 6.HbA1c ≥7.0% and ≤10.0%.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Patients should not enter the study if any of the following exclusion criteria are fulfilled. 1.Any clinically significant abnormality identified on physical examination or laboratory tests that would compromise patient?s safety or successful participation in the study as judged by the investigator. 2.Patients who have previously been intolerant to or non-compliant with a total daily dose of metformin higher than 1500 to 1700 mg. 3.Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketonic coma. 4.Pregnant or breastfeeding patients. 5.Prior use of insulin or injectable GLP-1 analogue (exenatide or liraglutide) within 3 months of the study start. 6.Treatment with systemic glucocorticoids other than replacement therapy. Inhaled, local injected and topical use of glucocorticoids are allowed. 7.Treatment with cytochrome P450 3A4 (CYP450 3A4) inducers, eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin and St. John?s Worth, and cytochrome P450 3A4/5 (CYP450 3A4/5) inhibitors, eg, delavirdine, indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole (topical use is allowed), nefazodone, saquinavir and telithromycin. 8.Potential allergy to saxagliptin, placebo or formulation excipients. 9.Past hypersensitivity reaction to a DPP-4 inhibitor. 10.Contraindications to therapy as outlined in the saxagliptin Investigator?s Brochure. 11.Contraindications to therapy as outlined in the metformin package insert including conditions leading to an increased risk of hypoxemia and lactic acidosis. 12.History of haemoglobinopathies (sickle cell anaemia or thalassemias, sideroblastic anaemia). 13.History of alcohol abuse or illegal drug abuse within the past 12 months. 14.Involvement in the planning and conduct of the study (applies to both AstraZeneca and Bristol-Myers Squibb personnel or personnel at the study centre). 15.Participation in a clinical study during the past 3 months prior to Visit 1. 16.Donation of blood, plasma or platelets within the past 3 months prior to Visit 1. 17.Individuals who, in the opinion of the investigator, in which participation in this study may pose a significant risk to the patient and could render the patient unable to successfully complete the study. 18.Suspected or confirmed poor protocol or medication compliance as judged by the investigator. Additional Exclusion criteria at Visita 2: 19.Serum creatinine ≥133 μmol/L (≥1.5 mg/dL) for men or ≥124 μmol/L (≥1.4 mg/dL) for women. 20.Active liver disease and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3xULN and/or total bilirubin >34 μmol/L (>2.0 mg/dL). 21.Creatine kinase (CK) ≥10xULN.

研究者

发起方

ASTRAZENECA

相似试验

进行中（未招募）

不适用

A 24-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Add-on Compared to Uptitration of Metformin in Patients with Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Sub-Maximal Doses of Metformin - Prompton-insulin dependent type 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10029505Term: Non-insulin-dependent diabetes mellitus

EUCTR2009-012775-10-GBAstraZeneca AB268

进行中（未招募）

不适用

EUCTR2009-012775-10-BEAstraZeneca AB268

进行中（未招募）

1 期

EUCTR2009-012775-10-FRAstraZeneca AB268

进行中（未招募）

不适用

EUCTR2009-012775-10-DEAstraZeneca AB268

已完成

4 期

inaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

CTRI/2012/10/003082Boehringer Ingelheim Pharmaceuticals270